---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-23-000019"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T21:01:40.097228+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vertex Q2 product revenue $2.49B (+14% YoY); raises FY 2023 guidance to $9.7-9.8B

## Summary
- Q2 product revenue $2.49B, up 14% vs Q2 2022; U.S. revenue $1.51B (+7%), OUS $985M (+26%).
- Full-year CF product revenue guidance raised to $9.7-$9.8B from $9.55-$9.7B; R&D/SG&A guidance also raised.
- FDA accepted exa-cel BLAs for SCD & TDT; Priority Review for SCD, PDUFA Dec 8, 2023; TDT PDUFA Mar 30, 2024.
- Vanzacaftor triple SKYLINE & RIDGELINE studies expected to complete by end of 2023; results in early 2024.
- VX-548 pivotal program in acute pain expected to complete late 2023; results late 2023/early 2024.

## SEC filing metadata
- accession: 0000875320-23-000019
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532023000019/0000875320-23-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532023000019/vrtx-20230801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-23-000019
- JSON: https://secwatch.observer/filing/0000875320-23-000019.json
- Plain text: https://secwatch.observer/filing/0000875320-23-000019.txt

## Key facts
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA reported the second quarter ended June 30, 2023 results: revenue $2.49 billion. Guidance raised.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $2.49 billion
  - Guidance: raised
  - Result: reported results
  source text: Vertex Reports Second Quarter 2023 Financial Results — Product revenue of $2.49 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000019/0000875320-23-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.